<p>Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.</p>

Dr. David Jackman of Dana-Farber Cancer Institute discusses how after introduction of a clinical pathway in metastatic NSCLC, cost of care decreased significantly with no compromise in survival.

Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer

JCO OP: Put Into Practice highlights new research published in JCO OP related to cancer care delivery, quality, disparities, access. Host Dr. Fumiko Chino, MD FASCO interviews thought leaders in oncology to give listeners practical knowledge that can be used in day-to-day practice along with solution-oriented discussions and care innovations.

Share Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer

Sign up to save your podcasts

Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer

Cost and Survival Analysis before and after Implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer

More shows like JCO Oncology Practice Podcast

JAMA Editors' Summary

WSJ Your Money Briefing

NEJM This Week

Journal of Clinical Oncology (JCO) Podcast

JAMA Clinical Reviews

ASCO Daily News

The Curbsiders Internal Medicine Podcast

JAMA Medical News

ASCO Guidelines

Plenary Session - inactive due to federal service

Harrison's PodClass: Internal Medicine Cases and Board Prep

The Big Take

Two Onc Docs

This Day in AI Podcast

The Wirecutter Show